Lever
Lifestyle
- Regular physical activity
- Weight management
- Smoking cessation
Blutwerte · Marker
Non-HDL-Cholesterin
Non-HDL Cholesterol · Non-HDL-C
Lipide & Herz-Kreislauf
- Einheit:
- mmol/L
- Abbreviation
- Non-HDL-C
Non-HDL cholesterol measures the total cholesterol content in lipoproteins that are considered atherogenic, excluding HDL cholesterol.
Reference Ranges
Reference
0–3.9mmol/L
0
2.6
3.9
LowNormalHigh
Reference
Optimal
Unit · mmol/LNon-fasting samples are acceptable; values above 3.9 mmol/L are considered elevated.
Overview
Übersicht
Non-HDL cholesterol (Non-HDL-C) is a calculated blood lipid marker that represents the total cholesterol content minus the high-density lipoprotein cholesterol (HDL-C). It encompasses all atherogenic lipoproteins, including low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and lipoprotein(a). Researchers have found that Non-HDL-C is a significant predictor of cardiovascular disease (CVD) risk, as it reflects the total burden of cholesterol that can contribute to atherosclerosis. Elevated levels of Non-HDL-C are associated with increased risk of coronary artery disease, stroke, and peripheral vascular disease. In athletic and biohacking contexts, maintaining optimal Non-HDL-C levels is crucial for cardiovascular health and longevity. Athletes may monitor this marker to ensure their lipid profiles support optimal performance and recovery. Biohackers might target specific lifestyle and dietary interventions to optimize Non-HDL-C levels for enhanced healthspan. Researchers observed that Non-HDL-C levels are not significantly affected by fasting status, making it a convenient marker for routine lipid profiling. However, factors such as acute illness, medication use, and genetic predispositions can influence Non-HDL-C levels, necessitating careful interpretation in clinical practice.
Klinische Bedeutung
Elevated Non-HDL-C levels indicate a higher risk of cardiovascular diseases due to the presence of atherogenic lipoproteins. Lower levels are generally associated with a reduced risk of atherosclerosis and related conditions.
Dynamics
Trend Interpretation
Rising Values
Progressively rising Non-HDL-C suggests worsening lipid profile and increased cardiovascular risk. Retest in 4-6 weeks if outside optimal range.
Falling Values
Falling values may indicate improved lipid management and reduced cardiovascular risk.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Poor diet high in saturated fats
- Genetic predispositions
- Obesity
- Sedentary lifestyle
- Diabetes
- Hypothyroidism
Cause
Low Levels
- Hyperthyroidism
- Malabsorption syndromes
- Chronic liver disease
- Malnutrition
- Certain medications
Protocol
How to Optimize
Lever
Nutrition
- Increase intake of omega-3 fatty acids
- Consume more fiber-rich foods
- Limit saturated and trans fats
Lever
Supplementation
- Omega-3 fish oil
- Plant sterols
Note:
Consult a healthcare provider before starting any supplementation, especially if on medication.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Annually for healthy adults, more frequently if at risk for CVD.
Interfering Factors
- Acute illness
- Recent major surgery
- Certain medications
Related Peptides & Hormones
Apolipoprotein B
hormone or peptideDirectly measures
Open Research Questions
Current research suggests that reference ranges and optimal targets for non-HDL cholesterol (non-HDL-C) remain debated, particularly in diverse populations. Researchers have not yet established the impact of confounders such as age, sex, and comorbidities on the clinical utility of non-HDL-C in various conditions, including sepsis and gout. Unanswered clinical questions include the specific thresholds of non-HDL-C that predict cardiovascular events across different demographics and the role of non-HDL-C in guiding treatment decisions.
22 Research Publications
1,049
Total Citations
8
Human/RCT
6.5
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.
Nordestgaard Børge G, et al. · European heart journal · 2016
ReviewInfluence29.0
786
Researchers found that non-fasting lipid profiles provide comparable results to fasting profiles for assessing cardiovascular disease risk. They recommend routine use of non-fasting samples for lipid testing, flagging abnormal values based on specific concentration cut-points. This approach aims to improve patient compliance with lipid testing.
Key findings
- 01Researchers observed that changes in lipid levels after eating are minimal and not clinically significant.
- 02They found that non-fasting and fasting lipid profiles can predict cardiovascular disease risk similarly.
- 03The study suggests flagging abnormal lipid levels in lab reports to help identify potential health issues.
02Top
#02
Ezetimibe: cholesterol lowering and beyond.
ReviewInfluence4.0
150
Researchers examined ezetimibe, a cholesterol absorption inhibitor, noting its effects on lowering LDL cholesterol and potentially improving other lipid parameters, including non-HDL-C. The clinical significance of these effects is under ongoing evaluation.
03Top
#03
Update on the laboratory investigation of dyslipidemias.
Review
40
Researchers reviewed the evolving role of clinical laboratories in assessing cardiovascular disease risk through lipid measurements. They highlighted non-HDL-C as a valuable alternative for evaluating lipid profiles and emphasized the need for standardization in testing methods.
04
#04
Hypertriglyceridemia in Obese Children and Adolescents.
HumanInfluence2.0
34
This study addressed hypertriglyceridemia in obese children and adolescents, linking elevated triglyceride levels to cardiometabolic risk. Researchers recommended universal lipid screening, including non-HDL-C measurements, to identify at-risk youth.
05
#05
The clinical and laboratory investigation of dysbetalipoproteinemia.
ReviewInfluence2.0
13
Researchers reviewed familial dysbetalipoproteinemia, a genetic disorder linked to increased cardiovascular risk. They noted that standard lipid profiles often fail to diagnose this condition, emphasizing the need for specialized tests like beta quantification. The study advocates for using apolipoprotein B as an initial screening tool.
06
#06
Laboratory evaluation of lipid parameters in clinical practice.
ReviewInfluence1.0
8
This review discussed the importance of accurate lipid measurements for coronary artery disease prevention. Researchers emphasized the need for standardized non-fasting lipid profiles, including non-HDL-C, for effective risk estimation and treatment guidance.
07
#07
Association of 28-day mortality with non-high-density lipoprotein cholesterol and the high-density lipoprotein cholesterol ratio (NHHR) in patients with sepsis: Results of MIMIC-IV database analysis.
Human
8
Researchers examined the relationship between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and 28-day mortality in sepsis patients. They found that a higher NHHR was associated with increased mortality risk, suggesting that NHHR could be a valuable prognostic marker in sepsis. The study involved over 3,000 patients.
08
#08
Association of non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) with gout prevalence: a cross-sectional study.
HumanInfluence1.0
7
Researchers investigated the association between the NHHR and gout prevalence using data from a large national survey. They found that higher NHHR levels significantly correlated with increased odds of developing gout, indicating NHHR as a potential marker for gout risk. The study included over 30,000 participants.
09
#09
Cardiovascular disease lipids and lipoproteins biomarker standardization.
Review
2
Researchers reviewed the standardization of cardiovascular disease lipid and lipoprotein biomarker measurements, emphasizing the importance of assay standardization for reliable results. They highlighted that non-HDL cholesterol (non-HDL-C) is included in standardization efforts to improve patient care and CVD risk assessment.
10
#10
Prognostic Value of Non-HDL Cholesterol in COVID-19 Pneumonia.
Human
1
This study investigated the prognostic value of non-HDL-C levels measured before COVID-19 infection. Researchers found that non-HDL-C was an independent risk factor for mortality in COVID-19 patients, suggesting its potential as a prognostic biomarker.
Publication Trend
Research publications about Non-HDL-Cholesterin over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer